There are currently 10 active clinical trials seeking participants for Ocular Hypertension research studies. The states with the highest number of trials for Ocular Hypertension participants are California, Texas, Florida and Georgia.
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
NCT04647214
Recruiting
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: Angeles Eye Institute /ID# 240368, Culver City, California +38 locations
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Walman Eye Center /ID# 252153, Sun City, Arizona +32 locations
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
NCT05913232
Recruiting
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Global Research Management, Glendale, California +8 locations
Conditions: Glaucoma Open-Angle Primary, Ocular Hypertension
Register for Updates
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT04630808
Recruiting
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Gender:
All
Ages:
Between 18 years and 84 years
Trial Updated:
02/23/2024
Locations: Nicox Clinical Site, Dothan, Alabama +87 locations
Conditions: Open Angle Glaucoma, Ocular Hypertension
Register for Updates
Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
NCT05273385
Recruiting
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Glaucoma, Ocular Hypertension, Open Angle Glaucoma
Register for Updates
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
NCT06120842
Recruiting
This trial is a randomized study to evaluate and compare two doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Gender:
All
Ages:
22 years and above
Trial Updated:
11/01/2023
Locations: Arizona Advanced Eye Research Institute, Glendale, Arizona
Conditions: Cataract, Glaucoma, Ocular Hypertension
Register for Updates
Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
NCT05844384
Recruiting
This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2023
Locations: Wilford Hall Ambulatory Surgical Center, Lackland Air Force Base, Texas
Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Register for Updates
Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension
NCT04500574
Recruiting
In this research study, we will assess the safety, tolerability, comfort, and feasibility of lowering intraocular pressure using a novel Contact Lens Drug Delivery System with latanoprost. Latanoprost is a well-studied medication and has been used to treat glaucoma for decades. Currently, latanoprost is FDA-approved to be administered to patients as eye drops, but using eye drops has challenges (having to remember to take the drop, getting the drop in the eye). This clinical trial is being done... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/04/2023
Locations: Massachusetts Eye and Ear, Boston, Massachusetts
Conditions: Glaucoma, Ocular Hypertension
Register for Updates
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
NCT05401357
Recruiting
This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/09/2022
Locations: Eye Research Foundation Inc., Newport Beach, California +8 locations
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Register for Updates
Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension
NCT05277870
Recruiting
The purpose of this study is to evaluate the safety, efficacy, and usability of an eyedrop bottle adaptor that creates smaller eyedrops, Nanodropper, in an open-angle glaucoma/ocular hypertension patient population.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/03/2022
Locations: University of Washington, Seattle, Washington
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Register for Updates